A systematic review and meta‐analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections

泊沙康唑 中止 医学 内科学 氟康唑 不利影响 伏立康唑 伊曲康唑 两性霉素B 荟萃分析 入射(几何) 优势比 死亡率 氟胞嘧啶 抗真菌 皮肤病科 物理 光学
作者
Hideo Kato,Mao Hagihara,Nobuhiro Asai,Takumi Umemura,Jun Hirai,N. Môri,Yuka Yamagishi,Takuya Iwamoto,Hiroshige Mikamo
出处
期刊:Mycoses [Wiley]
卷期号:66 (9): 815-824 被引量:11
标识
DOI:10.1111/myc.13622
摘要

Abstract Background Isavuconazole is a novel triazole antifungal agent. However, the previous outcomes were highlighted by statistical heterogeneity. This meta‐analysis aimed to validate the efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections (IFIs) compared with other antifungal agents (amphotericin B, voriconazole and posaconazole). Methods Scopus, EMBASE, PubMed, CINAHL and Ichushi databases were searched for relevant articles that met the inclusion criteria through February 2023. Mortality, IFI rate, discontinuation rate of antifungal therapy and incidence of abnormal hepatic function were evaluated. The discontinuation rate was defined as the percentage of therapy discontinuations due to adverse events. The control group included patients who received other antifungal agents. Results Of the 1784 citations identified for screening, 10 studies with an overall total of 3037 patients enrolled. Isavuconazole was comparable with the control group in mortality and IFI rate in the treatment and prophylaxis of IFIs, respectively (mortality, odds rate (OR) 1.11, 95% confidential interval (CI) 0.82–1.51; IFI rate, OR 1.02, 95% CI 0.49–2.12). Isavuconazole significantly reduced the discontinuation rate in the treatment (OR 1.96, 95% CI 1.26–3.07) and incidence of hepatic function abnormalities in the treatment and prophylaxis, compared with the control group (treatment, OR 2.31, 95% CI 1.41–3.78; prophylaxis, OR 3.63, 95% CI 1.31–10.05). Conclusions Our meta‐analysis revealed that isavuconazole was not inferior to other antifungal agents for the treatment and prophylaxis of IFIs, with substantially fewer drug‐associated adverse events and discontinuations. Our findings support the use of isavuconazole as the primary treatment and prophylaxis for IFIs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
安详绿草完成签到,获得积分10
刚刚
li发布了新的文献求助10
1秒前
lapidary发布了新的文献求助10
2秒前
aurora发布了新的文献求助30
2秒前
2秒前
聪慧小霜应助聪明的幻枫采纳,获得10
2秒前
2秒前
4秒前
英姑应助小学教材全解采纳,获得10
4秒前
慕青应助163采纳,获得10
5秒前
5秒前
科研通AI5应助甜美代秋采纳,获得10
6秒前
飘逸小笼包完成签到,获得积分10
6秒前
华仔应助lapidary采纳,获得10
7秒前
BQ发布了新的文献求助10
7秒前
7秒前
9秒前
嘻嘻完成签到 ,获得积分10
9秒前
Sinner完成签到,获得积分10
9秒前
善学以致用应助小汁儿采纳,获得10
9秒前
aurora完成签到,获得积分10
9秒前
qin发布了新的文献求助10
10秒前
王倩发布了新的文献求助20
10秒前
庸人自扰完成签到,获得积分10
10秒前
10秒前
YooM发布了新的文献求助10
10秒前
manzhouwang发布了新的文献求助30
11秒前
Leon发布了新的文献求助10
12秒前
Aulalala完成签到,获得积分10
12秒前
完美夏天发布了新的文献求助10
12秒前
li完成签到 ,获得积分10
13秒前
13秒前
15秒前
aike发布了新的文献求助50
16秒前
BQ完成签到,获得积分10
16秒前
Rondab应助万历采纳,获得10
16秒前
moon发布了新的文献求助10
17秒前
17秒前
完美夏天完成签到,获得积分10
19秒前
量子星尘发布了新的文献求助10
19秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969628
求助须知:如何正确求助?哪些是违规求助? 3514448
关于积分的说明 11174217
捐赠科研通 3249822
什么是DOI,文献DOI怎么找? 1795000
邀请新用户注册赠送积分活动 875537
科研通“疑难数据库(出版商)”最低求助积分说明 804856